JNJ vs MDXG

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

Score Change Explanation: The significant upward revision in score from 5.8 to 7.9 is primarily driven by the robust Q4 and full year 2025 earnings report. The company demonstrated strong financial progress with Q4 net sales growing 27% year-over-year and, crucially, reported positive GAAP net income of $15 million and adjusted EPS of $0.14. This tangible return to profitability and accelerated re...